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Acute myeloid leukemia (AML) 
Definition 
Synonyms: 
• Acute myelocytic leukemia 
• Acute myelogenous leukemia 
• Acute nonlymphocytic leukemia 
• AML describes a heterogeneous group of clonal 
hematopoietic  progenitor cell disorders 
characterized by malignant neoplastic 
proliferation and accumulation in the bone 
marrow of immature and nonfunctional 
hematopoietic cells with a spectrum of 
morphologic, immunophenotypic, cytogenetic 
and molecular characteristics. 
 
 
Epidemiology  
• In adults, acute myelogenous leukemia (AML) 
represents about 90% of all acute leukemias. 
• The incidence rises with age, occurring rarely 
before age 40 (<1 in 100,000), and increasing 
to an incidence of 16 cases per 100,000 by age 
75.  
• The median age at diagnosis is 65 years. 
Risk factors 
1. Chemicals: Exposure to benzenes, pesticides, herbicides 
and cigarette smoking.  Exposure to chemotherapeutic 
agents particularly alkylating agents, topoisomerase-II 
inhibitors and taxanes 
2. Ionizing radiation: both  therapeutic and nontherapeutic 
3. Genetic diseases. A higher than average incidence is seen 
in individuals with Down’s syndrome, Klinfelter’s 
syndrome, Ataxia telangectasia, Kostman syndrome, 
neurofibromatosis or Fanconi anemia.  
4. Myelodysplastic syndromes or myeloproliferative 
disorders: there is also a greater incidence of AML in 
individuals with these pre-existing hematologic disorders 
Pathogenesis 
• AML is believed to be caused by the malignant transformation of a single 
hematopoietic stem cell. 
• Leukemic cells are characterized by increased clonal proliferation and/or 
decreased cell death(apoptosis) rate with a block in normal differentiation 
and maturation. Effect is expansion of the neoplastic clone with a 
decrease in normal cells 
• Leukemic transformation may occur at an early stage of hematopoiesis 
with the pluripotent stem cell, or, less often, with a committed stem cell. 
• The pathogenesis of acute leukemia also includes a critical role for 
oncogenes and anti-oncogenes. About 20% to 30% of leukemia cases are 
associated with mutations of the RAS oncogene, the most commonly 
detected molecular abnormalities in AML. Control of the proliferation and 
differentiation of many types of cells involves RAS gene products. 
• In summary, leukemogenesis appears to be a multistep process involving a 
susceptible hematopoietic cell, a genetic event (oncogenes, chromosomal 
translocations), and possibly environmental influences (chemical, 
radiation). 
FAB Classification 
• Two classification systems are used to 
categorize AML. The first is the classic French 
American British (FAB) typing classification, 
based on morphology and cytochemical 
characteristics, and immunophenotype of 
peripheral blood and bone marrow.  
• The FAB classification defines AML as > 30% 
blasts in the marrow.  
• It divides AML into eight subtypes. 
The FAB Classification System for 
Acute Myelogenous Leukemia 
 • M0 Acute Myeloid Leukemia Without 
Differentiation or Maturation 
• M1 Acute Myeloid Leukemia Without Maturation 
• M2 Acute Myeloid Leukemia With Maturation 
• M3 Acute Promyelocytic Leukemia (APL) 
• M4 Acute Myelomonocytic Leukemia 
• M5 Acute Monocytic Leukemia 
• M6 Erythroleukemia 
• M7 Acute Megakaryoblastic Leukemia 
WHO Classification 
• The new World Health Organization (WHO) classification  
defines AML as >20% blasts in the marrow or blood.  
• Like the FAB classification, is based on cellular morphology, 
cytochemistry and immunophenotyping, but adds cytogenetic 
abnormalities and clinical syndromes for disease 
categorization. The prognostic importance of cytogenetic 
information supports its inclusion in this classification system.  
• The WHO classification divides AML into 5 subtypes. It 
includes leukemias which are secondary to 
myelodysplastic/myeloproliferative syndromes, or to prior 
treatment with cytotoxic chemotherapy and/or radiotherapy. 
Acute myeloid leukemia (WHO 2008) 
• Acute myeloid leukemia with recurrent genetic abnormalities 
•     AML with t(8;21)(q22;q22); RUNX1-RUNX1T1 
•     AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 
•     APL with t(15;17)(q22;q12); PML-RARA* 
•     AML with t(9;11)(p22;q23); MLLT3-MLL† 
•     AML with t(6;9)(p23;q34); DEK-NUP214 
•     AML with inv(3)(q21q26.2) or t(3;3)(q21;q26.2); RPN1-EVI1 
•     AML (megakaryoblastic) with t(1;22)(p13;q13); RBM15-MKL1 
•     Provisional entity: AML with mutated NPM1 
•     Provisional entity: AML with mutated CEBPA 
• Acute myeloid leukemia with myelodysplasia-related changes‡ 
• Therapy-related myeloid neoplasms• 
• Acute myeloid leukemia, not otherwise specified (NOS) 
•     Acute myeloid leukemia with minimal differentiation 
•     Acute myeloid leukemia without maturation 
•     Acute myeloid leukemia with maturation 
•     Acute myelomonocytic leukemia 
•     Acute monoblastic/monocytic leukemia 
•     Acute erythroid leukemia 
•         Pure erythroid leukemia 
•         Erythroleukemia, erythroid/myeloid 
•     Acute megakaryoblastic leukemia 
•     Acute basophilic leukemia 
•     Acute panmyelosis with myelofibrosis (syn.: acute myelofibrosis; acute myelosclerosis) 
• Myeloid sarcoma (syn.: extramedullary myeloid tumor; granulocytic sarcoma; chloroma) 
• Myeloid proliferations related to Down syndrome 
•     Transient abnormal myelopoiesis (syn.: transient myeloproliferative disorder) 
•     Myeloid leukemia associated with Down syndrome 
• Blastic plasmacytoid dendritic cell neoplasm 
• Acute leukemias of ambiguous lineage 
•     Acute undifferentiated leukemia 
•     Mixed phenotype acute leukemia with t(9;22)(q34;q11.2); BCR-ABL1‖ 
•     Mixed phenotype acute leukemia with t(v;11q23); MLL rearranged  
•     Mixed phenotype acute leukemia, B/myeloid, NOS 
•     Mixed phenotype acute leukemia, T/myeloid, NOS 
•     Provisional entity: Natural killer (NK)–cell lymphoblastic leukemia/lymphoma 
De novo and Secondary AML  
• De novo AML should refer to patients with no 
clinical history of prior myelodysplastic 
syndrome, myeloproliferative disorder or 
exposure to potentially leukemogenic 
therapies or agents. 
• Secondary AML should refer to patients with 
prior hematologic disease. 
http://www.albertahealthservices.ca/hp/if-hp-
cancer-guide-lyhe006-aml.pdf 
History and Physical Examination 
• In the history, common presenting symptoms are 
fatigue, easy bruising and frequent infections. 
• Examination may reveal pallor and signs of 
hemorrhage (oral hemorrhagic bullae, petechiae, 
and ecchymoses). 
• Chloromas 
• Gingival hyperplasia, lymphadenopathy, 
hepatosplenomegaly, and skin infiltration 
(leukemia cutis) may be observed, which are 
more common in the monocytic subtypes of AML 
(FAB M4 & M5). 
Physical Examination: Chloromas 
• Chloroma  (a myeloid sarcoma) is an extramedullary manifestation of acute 
myeloid leukemia characterized by a solid collection of leukemic cells 
occurring outside of the bone marrow. 
• The term chloroma results from the greenish color of these tumors caused 
by the presence of myeloperoxidase.  
• Chloromas may occur in virtually any organ or tissue. The most common 
areas of involvement are the skin (also known as leukemia cutis) and the 
gums. 
• Skin involvement typically appears as violaceous, raised, nontender plaques 
or nodules, which on biopsy are found to be infiltrated with myeloblasts. 
Gum involvement (gingival hypertrophy) leads to swollen, sometimes painful 
gums which bleed easily with tooth brushing and other minor trauma. 
• Other tissues which can be involved include lymph nodes, the small 
intestine, the mediastinum, the lung, epidural sites, the uterus, the ovaries, 
and the orbit of the eye.  
• Central nervous system involvement, as described above, most often takes 
the form of meningeal leukemia, or invasion of the subarachnoid space by 
leukemic cells.  
Physical Examination 
• Hyperuricemia is the most common biochemical abnormality 
during treatment of acute leukemia. It generally results from the 
high turnover rate of the proliferating leukemic cells and can 
lead to urate precipitation, obstructive uropathy, and acute renal 
failure. All patients should receive vigorous intravenous 
hydration and therapy with allopurinol prior to chemotherapy. 
• Tumour lysis syndrome may occur with initiation of treatment as 
a complication of intensive cytotoxic chemotherapy or in 
patients with rapidly rising or very high blast counts. This may 
result in potentially life-threatening metabolic complications, 
including hyperkalemia, hyperphosphatemia, hypocalcemia, and 
hyperuricemia. 
• Disseminated intravascular coagulation (DIC) is common at 
presentation for leukemic patients, with subtype FAB M3 (acute 
promyelocytic leukemia). Coagulation screening is performed at 
initiation of workup.  
Gum hypertrophy 
Gum hypertrophy 
A 
B 
C 
Chloromas 
NEJM 1998 
Orbital chloroma 
                  
                       
Leukemia, extramedullary, Case 01-001.jpg Leukemia, extramedullary, Case 01-002.jpg 
Leukemic colitis in 75-year-old woman with 
AML M4 
Pulmonary chloromas before and after 
the treatment  
Hemorrhagic syndrome 
Algorithm of diagnosis 
• The diagnosis is often suspected and can at times 
be confirmed from the peripheral blood.  
• All patients being considered for therapy should 
undergo a bone marrow aspiration and biopsy.  
• Bone  marrow aspiration samples should be sent 
for: 
• Morphology  
• Cytochemistry 
• Immunophenotyping  
• Cytogenetics 
Peripheral Blood Findings 1 
• Blast forms are nearly always present on examination of the peripheral 
smear. Only a small percentage of patients may present without circulating 
leukemic cells.  
• Hiatus  leukemicus  - A condition observed in acute myelogenous leukemia 
in which there are numerous myeloblasts and a number of mature 
neutrophils in the peripheral blood, with few or no intermediate forms. The 
term "hiatus leukemicus" suggests a jump in cell development from an early 
stage to a late stage with nothing in between, analogous to changing from 
the appearance of a 10 year old to that of a 60 year old without any 
intermediate stages.  
• Auer rods are clumps of azurophilic granular material that form elongated 
needles seen in the cytoplasm of leukemic blasts. They are composed of 
fused lysosomes and contain peroxidase, lysosomal enzymes, and large 
crystalline inclusions. Morphologically, the Auer "rods" come in all sizes and 
shapes. They have been described as needle-shapes with pointed ends 
(most common), comma-shapes, and diamond-shapes; others were long 
and rectangular. More appropriately, they can be referred to as Auer bodies.  
• Anemia and/or thrombocytopenia.  Most patients with AML present with 
anemia and/or thrombocytopenia. 
 
Peripheral Blood Findings 2 
• Patients may present with a total WBC which is elevated, within 
the normal range, or below the normal range. Five to twenty 
percent of patients will present with markedly elevated WBC 
(>100 x 109/L). 
• Leukemia variant according to the number of white blood cells: 
1. Leukemic that are characterized by a significant increase in the 
number of WBC, including leukemia cells in peripheral blood 
(tens or hundreds of thousands, sometimes millions in 1 /mcL of 
blood). This is the most common form. 
2. Subleukemic – the WBC count is slightly elevated - up to 30 000 
in 1 mcL of blood. 
3. Aleukemic –  the number of WBC is whithin the normal range  
and tumor cells are not present in the blood. This type is rare, 
but it usually occurs in the early stages of the disease.  
4. Leukopenic   –  the number of WBC is below normal 
Aspiration and biopsy of bone marrow 
• Aspiration and biopsy of bone marrow, usually from the 
superior posterior iliac crest, is routinely performed by the 
hematologist to confirm the diagnosis of acute leukemia. 
Aspirate samples are sent for morphologic, histocytochemical, 
immunophenotypic, cytogenetic, and molecular analysis to 
enable classification of the leukemia.  
The threshold number of blasts in the bone marrow  
is 20% or more.  
• Exceptions include AML with t (8;21), inv(16) or t(15;17), in 
which the diagnosis of AML is made regardless of the 
percentage of bone marrow blasts. 

Cytochemistry 
• Histocytochemical staining of bone marrow biopsy 
samples can distinguish myeloid from lymphoid 
leukemias, and may help to classify the subtypes of 
AML using myeloperoxidase (MPO) or Sudan black B 
(SBB) and nonspecific esterase (NSE) stains.  
• Detection of MPO (if present in ≥ 3% of blasts) 
indicates myeloid differentiation, but its absence 
does not exclude a myeloid lineage because early 
myeloblasts and monoblasts may lack MPO.  
• SBB staining parallels MPO but is less specific.  
• NSE stains show diffuse cytoplasmic activity in 
monoblasts (usually > 80% positive) and monocytes 
(usually > 20% positive) 
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Fig. 1. Positive for MPO blasts (M3) (bone marrow).  
Fig. 2. Positive for MPO in neutrophils and negative in blasts in ALL (L2).  
 
  



M3  "angel wings"- Wright-Giemsa stain, 1000x  

 M4 Auer rods and hand-mirror appearing blasts 
 Wright-Giemsa, 1000x  

Cytogenetics 
• Since chromosomal abnormalities are associated with specific leukemia subtypes, 
response to therapy, and prognosis, cytogenetic analysis of bone marrow is an 
important component of the evaluation of a leukemic patient. 
• Induction treatment may begin before cytogenetic results are available (using FAB 
classification), but decisions regarding consolidation are often based on cytogenetic 
risk groups. 
t(8;21) at diagnosis. The karyotype at diagnosis with a t(8;21) (arrows) as the 
only cytogenetic change. This translocation is usually seen in AML (M2) often 
associated with Auer rods, marrow eosinophilia, and a favorable prognosis. 
www.meds.com/leukemia/ guide/guide_chapter3.html 
Normal chromosomes during complete remission. 
All chromosomes appear normal. No karyotypes 
with t(8;21) were seen. 

Immunophenotyping 
• The immunophenotype of bone marrow cells is determined using monoclonal 
antibodies that recognize myeloid- and lymphoid-specific glycoprotein antigens 
(referred to as clusters of differentiation or CDs) on the surface of normal and 
leukemic hematopoietic cells.  
• AMLs usually express the following Immunophenotypes:  
 All AML cells- CD13, CD15, CD33 
  Monocytoid AML cells- CD14 
 Blast cells (all lineages, particularly primitive cells)- CD34 
www.classimed.de/ eurocel2.html 
Prognosis  
• The median survival for untreated or refractory 
AML is usually a few weeks to 2-3 months. 
• Patients who do not receive consolidation 
therapy will relapse, usually within 6 to 9 months.  
• Despite the use of current induction and 
consolidation chemotherapy, most patients will 
eventually relapse and die of acute leukemia. 
Median survival is about 2 years (for patients < 60 
years) and less for older patients. 
• Approximately 25% to 40% of patients with AML 
treated with chemotherapy are alive and free of 
disease 5 years after diagnosis. 
Acute lymphoblastic leukemia 
(ALL) 
Definition 
• Neoplastic disease which results from a 
mutation in a single lymphoid progenitor cell 
at one of several discrete stages of 
development B or T cells 
Epidemiology 
• Leukaemia is the most common malignancy in 
children and accounts for one-third of all 
childhood cancers.  
• Approximately 3/4 of all cases of childhood 
leukaemia are ALL.  
• About 3,000 children in the United States and 
5,000 children in Europe are diagnosed with ALL 
each year.  
• The peak incidence of ALL occurs between age 2 
and 5 years. The incidence of ALL is higher 
among boys than girls.  
French American British 
Classification 
• L1: small uniform blasts  
• L2: larger, more variable sized blasts  
• L3: uniform cells with basophilic and sometimes 
vacuolated cytoplasm  
Immunologic 
Subtype 
% of cases FAB Subtype Cytogenetic 
Abnormalities 
Pre-B ALL 75 L1, L2 t(9;22), t(4;11), 
t(1;19) 
T cell ALL 20 L1, L2 14q11 or 7q34 
B cell ALL 5 L3 t(8;14), t(8;22), 
t(2;8) 
From: Harrison’s Principles of Internal Medicine, 16th 
ed. 2005. Chapter 97, Malignancies of lymphoid cells. 
WHO Classification 
• Precursor lymphoid neoplasms 
• B lymphoblastic leukaemia/lymphoma 
• B lymphoblastic leukaemia/lymphoma, NOS 
• B lymphoblastic leukaemia/lymphoma with recurrent genetic 
abnormalities 
• B lymphoblastic leukaemia/lymphoma with t(9;22)(q34; q11.2); BCR-
ABL1 
• B lymphoblastic leukaemia/lymphoma with t(v;11q23); MLL 
rearranged 
• B lymphoblastic leukaemia/lymphoma with t(12;21)(p13; q22); TEL-
AML1 (ETV6-RUNX1) 
• B lymphoblastic leukaemia/lymphoma with Hyperdiploidy 
• B lymphoblastic leukaemia/lymphoma with hypodiploidy (hypodiploid 
ALL) 
• T lymphoblastic leukaemia/lymphoma 
http://asheducationbook.hematologylibrary.
org/content/2006/1/128.full.pdf 
Pathogenesis 
• Acquired Genetic Change in Chromosome 
– Change in number, ie ploidy 
– Change in structure 
• Translocations (most common) 
• Inversions 
• Deletions 
• Point mutations 
• Amplifications 
Changes in normal means of cell differentiation, proliferation, and 
survival 
Symptoms  
• The first symptoms are usually non-specific and include anorexia, irritability 
and lethargy. 
• Fever is the most common finding, occurring in approximately 60% of 
patients.  
• Progressive bone marrow failure leads to pallor (anemia),  bleeding 
(thrombocytopenia) and susceptibility to infections (neutropenia). Over one 
third of patients may present with a limp, bone pain, arthralgia or refusal to 
walk due to leukaemia infiltration of the periosteum, bone or joint, or to 
the expansion of the marrow cavity by leukaemia  cells.  
• Less  common signs and symptoms include headache, vomiting, respiratory 
distress, oliguria and anuria.  
• At initial diagnosis,  60 to 70% of children  have enlargement of the liver or 
spleen, usually asymptomatic. 
• Lymphadenopathy (usually painless, localized or generalized) due to 
leukaemia infiltration is an frequent presenting sign.  
CNS symptoms 
• Acute leukemia, in particular ALL, has the 
highest propensity to invade the meninges 
and result in leukemic meningitis (LM)  
– Headache (<5% cases) 
– Increased ICP 
• Vomiting 
• Lethargy 
• Papilledema 
– Cranial nerve abnormalities 
Physical Examination 
• Clinical and laboratory features at diagnosis in 
children with ALL   
https://www.orpha.net/data/patho/Pro/en/AcuteLymphoblasticLeukemia-FRenPro3732.pdf 
Leukemic infiltration of the 
meninges 
19 year old female with ALL 
 Axial contrast enhanced T1-weighted MR image demonstrates multiple 
enhancing subarachnoid nodules (arrows) consistent with leukemic meningitis.  
Peripheral Blood Findings  
Cytochemistry  
• Terminal deoxynucleotidyl transferase (Tdt): 
DNA polymerase in early lymphoblasts 
• PERIODIC ACID-SCHIFF (PAS) 
– Principle: 
– Periodic acid oxidizes glycogen, mucoproteins 
band other high molecular weight carbohydrate 
into ALDEHYDE 
– Aldehyde + colorless schiff reagent ---bright red 
pink 
Periodic Acid Schiff 
 
  Red deposit 
Immunophenotyping ALL 
Cytogenetic Abnormalities 
From: Jabbour, E. et al. Adult Acute Lymphoblastic 
Leukemia. Mayo Clinic Proc. 2005;80(11):1517-1527 
Prognosis 
• Overall better in children than in adults 
http://pediatrics.evms.edu/residency/resgoals/hemeonc/
hemeoncresallreview.pdf 
Prognosis  
Treatment of acute leukemias 
Goal of treatment 
• The goals of therapy are to eliminate the leukemic 
clone and to restore normal hematopoiesis.  
• A complete remission (CR) is defined as the presence of 
less than 5% blasts in the bone marrow and restoration 
of normal blood counts.  
• The length of patient survival correlates with achieving 
a CR and the duration of the CR. 
• Patients who have refractory disease or do not achieve 
CR (often with more than one attempt at induction 
therapy) usually die within 2 to 4 months of diagnosis, 
due to complications such as infection or bleeding. 
Treatment regimens  
• Induction therapy – is intended to induce a complete 
remission  via the elimination or significant reduction of 
tumor clone and normalization of hematopoesis 
• Consolidation  of therapy  - the goal of consolidation 
therapy is to eliminate residual leukemic cells, prevent 
relapse, and improve survival.  
• Maintenance treatment 
• Treatment of relapses - once the leukemia relapses, 
patient outcome is poor.  
• Therapy for refractory disease 
• Prevention of neuroleukemia 
• Chemotherapy  
• Molecularly targeted therapy 
• Radiation therapy 
• Prevention  neuroleukemia 
• Reduction  of splenomegaly 
• Radiation of painful bone sites  
• Preparation before a bone marrow 
transplantation 
• Allogeneic  Stem Cell Transplantation or 
Autologous Bone Marrow Transplantation 
Treatment strategies 
The end 
